Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Opus Genetics Inc (IRD)

Opus Genetics Inc (IRD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 172,410
  • Shares Outstanding, K 68,964
  • Annual Sales, $ 10,990 K
  • Annual Income, $ -57,530 K
  • EBIT $ -65 M
  • EBITDA $ -65 M
  • 60-Month Beta 0.41
  • Price/Sales 8.49
  • Price/Cash Flow N/A
  • Price/Book 27.11

Options Overview Details

View History
  • Implied Volatility 270.79% (+270.79%)
  • Historical Volatility 67.38%
  • IV Percentile 51%
  • IV Rank 23.79%
  • IV High 1,036.10% on 03/17/25
  • IV Low 31.89% on 09/16/25
  • Expected Move (DTE 21) 0.36 (15.26%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 4
  • Volume Avg (30-Day) 411
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 10,184
  • Open Int (30-Day) 7,389
  • Expected Range 1.98 to 2.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.10
  • Number of Estimates 5
  • High Estimate -0.06
  • Low Estimate -0.15
  • Prior Year -1.27
  • Growth Rate Est. (year over year) +92.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.88 +25.00%
on 01/12/26
3.05 -22.95%
on 01/27/26
+0.40 (+20.51%)
since 12/30/25
3-Month
1.70 +38.24%
on 11/18/25
3.05 -22.95%
on 01/27/26
+0.38 (+19.29%)
since 10/30/25
52-Week
0.65 +261.54%
on 04/10/25
3.05 -22.95%
on 01/27/26
+1.24 (+111.71%)
since 01/30/25

Most Recent Stories

More News
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

The trial is funded through Abu Dhabi’s Healthcare Research and Innovation Fund Clinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026 MERTK-related retinitis pigmentosa...

IRD : 2.36 (-5.60%)
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

- Multi-asset pipeline with significant targeted data readouts and milestones - - Two lead ophthalmic gene therapy programs in clinical trials with new data anticipated in 2026 - - Supplemental New Drug...

IRD : 2.36 (-5.60%)
The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside

These biotech bets are only for investors who can stomach volatility.

EYPT : 14.04 (-4.81%)
IRD : 2.36 (-5.60%)
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene...

IRD : 2.36 (-5.60%)
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene...

IRD : 2.36 (-5.60%)
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

RESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies...

IRD : 2.36 (-5.60%)
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited...

IRD : 2.36 (-5.60%)
Opus Genetics to Participate in Upcoming Investment Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene...

IRD : 2.36 (-5.60%)
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Emerging gene therapy administered through a one-time subretinal injection marks a major milestone for the inherited retinal disease community Initial data expected in Q1 2026 RESEARCH TRIANGLE...

IRD : 2.36 (-5.60%)
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

- Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated vision - - Successful FDA RMAT meeting provides the potential...

IRD : 2.36 (-5.60%)

Business Summary

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills,...

See More

Key Turning Points

3rd Resistance Point 2.89
2nd Resistance Point 2.81
1st Resistance Point 2.65
Last Price 2.36
1st Support Level 2.42
2nd Support Level 2.34
3rd Support Level 2.18

See More

52-Week High 3.05
Last Price 2.36
Fibonacci 61.8% 2.13
Fibonacci 50% 1.85
Fibonacci 38.2% 1.57
52-Week Low 0.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar